TheStreet.com RealMoney.com IPOPros.com TheStreetPros.com Your Money/Shopping Help
  Sorry, the page you requested could not be found

Sorry that you couldn't find the page you wanted.

Here are a couple of ways that can help you find that information successfully.

Content Search:

Quote Search:

(Stocks, ETFs, Mutual Funds)

TheStreet Directory

Dow Jones S&P 500 NASDAQ 10-Year Note
10,405.83 1,102.35 2,190.86 34.82
Oil *
71.98
UP
68.78
UP
6.41
UP
7.13
UP
0.59
10 Yr
3.48%
SPDR Gold
110.82
+0.67%
+0.58%
+0.33%
+1.72%
Data delayed 20 minutes


Commentary: Open Book
*New* Alerts! Please click here...

Winners and Losers from Reshuffling the Nasdaq 100
By Don Luskin
Special to TheStreet.com

12/15/00 9:43 AM ET


I wrote about the reconsititution of the S&P 500 Index earlier. To read that story, click here .

The final element of quintuple-witching day on Friday will be the annual reconstitution of the Nasdaq 100 Index.

That's when the index is both rebalanced in terms of the relative weightings of the component stocks, but it is also the opportunity for new stocks to enter the index (and for an equal number of stocks to be eliminated).

There's not very much money in index funds that track the Nasdaq 100, probably only $30 billion at most. That's almost nothing compared to the $1 trillion in S&P 500 index funds, and most of it is in a single fund: the trust underlying the Nasdaq 100 shares, the security known affectionately to traders as the "Triple-Q's."

Nevertheless, because some of the stocks entering and exiting the index are volatile and illiquid, buying pressure from the indexers should push up the prices of entering stocks and their selling pressure should push down the prices of those that are exiting.

Here are the stocks that are entering and exiting the index:

Company and Symbol Dollar value of trade indexers will have to make (millions) Number of shares indexers will have to trade (millions) Percentage of average daily volume indexers will have to trade
Entering - buy
BEA Systems (BEAS: Nasdaq) $435 5.5 55%
Check Point (CHKP:Nasdaq) 384 2.4 60%
Millennium Pharmaceutical (MLNM: Nasdaq) 212 3.7 90%
Exodus Communications (EXDS: Nasdaq) 223 7.3 81%
Flextronics International (FLEX: Nasdaq) 210 7.2 82%
Rational Software (RATL: Nasdaq) 140 3.1 82%
Human Genome Sciences (HGSI: Nasdaq) 151 1.90 62%
Mercury Interactive (MERQ: Nasdaq) 136 1.4 49%
Idec Pharamceuticals (IDPH: Nasdaq) 177 0.8 44%
Inktomi (INKT: Nasdaq) 69 1.6 32%
Abgenix (ABGX: Nasdaq) 80 1.2 98%
TMP Worldwide (TMPW: Nasdaq) 107 1.6 236%
Exiting - (sell)
Adaptec (ADPT: Nasdaq) (17) (1.4) 80%
American Power Conversion (APCC: Nasdaq) (59) (4.4) 202%
Apollo Group (APOL: Nasdaq) (44) (1.2) 258%
Dollar Tree Stores (DLTR: Nasdaq) (70) (1.7) 223%
Herman Miller (MLHR: Nasdaq) (24) (1.0) 340%
Legato Systems (LGTO: Nasdaq) (18) (1.6) 140%
Networks Associates (NETA: Nasdaq) (34) (2.4) 136%
Northwest Airlines (NWAC: Nasdaq) (32) (1.2) 301%
PacifiCare Health Systems (PHSY: Nasdaq) (7) (0.5) 83%
Quintiles Transnational (QTRN : Nasdaq ) (51) (2.8) 546%
Sigma-Aldrich (SIAL : Nasdaq ) (58) (1.4) 222%
Synopsys (SNPS : Nasdaq) (64) (1.3) 221%
MetaMarkets.com.

The Nasdaq 100 is designed to reflect the largest-cap and most liquid Nasdaq-listed stocks. So, as you'd expect, the stocks ejected from the index tend to be illiquid, low-cap names -- while the new stocks entering the index are the emerging big-cap superstars.

A quick glance at the winners and losers tells the story of the last year -- the emergence of new Internet infrastructure and biotech leaders. But a perverse result of this score-keeping process is that the total dollar value of entering stocks to buy is far greater than the total value of exiting stocks to sell.

The imbalance of buys over sells should be about $1.8 billion. As a result, indexers will have to sell $1.8 billion from across their portfolios. This will probably be implanted in the form of sell programs at the close on Friday.

$1.8 billion is a big program to implement all at once. If that's the way this trade is executed, we could be in for a rough close.


Don Luskin is President and CEO of MetaMarkets.com, and a portfolio manager of OpenFund. At time of publication, OpenFund was long Check Point Software, Millennium Pharmaceutical, Human Genome Sciences and Abgenix. Luskin appreciates your feedback and invites you to send it to Don Luskin .
Send letters to the editor to letters@realmoney.com.
Read our conflicts and disclosure policy.
Order reprints of RealMoney.com articles. Top

Research Now
on DLJdirect
BEAS CHKP HGSI
Visit the DLJdirect Research Center

RELATED STORIES


Open Book
What Biotech Bubble?12/7/00 9:26 AM ET
Value the biotech industry on a reasonable yardstick -- market cap per potential drug -- and biotechs are no more expensive than the big pharmas.

Open Book
What Biotech Bubble? (cont'd) Hougan's Model Proves None Exists12/7/00 9:24 AM ET
Using a reasonable yardstick, market cap per drug, biotechs are no more expensive than big pharmas.

Open Book
Hunting Season on the S&P12/6/00 5:39 PM ET
Every time a stock joins the index, it's possible to make money by exploiting the index fund managers.



Click to change or update chart Click to change or update chart Click to change or update chart

Sorry, the page you requested could not be found

Sorry that you couldn't find the page you wanted.

Here are a couple of ways that can help you find that information successfully.

Content Search:

Quote Search:

(Stocks, ETFs, Mutual Funds)

TheStreet Directory

Dow Jones S&P 500 NASDAQ 10-Year Note
10,405.83 1,102.35 2,190.86 34.82
Oil *
71.98
UP
68.78
UP
6.41
UP
7.13
UP
0.59
10 Yr
3.48%
SPDR Gold
110.82
+0.67%
+0.58%
+0.33%
+1.72%
Data delayed 20 minutes